Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Net Asset Momentum
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd net asset momentum. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) recorded a net asset momentum of 6.7% as of December 2024, with net assets of CN¥2.46 Billion CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Explore reinvestment intensity of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd to see what proportion of operating cash flow is directed to capital expenditures.
YoY Momentum
Current Net Assets
Years of Data
Country
Net Asset Momentum of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
Net asset momentum of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024. This chart tracks Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's year-over-year net asset growth across 16 annual reporting periods from 2009 to 2024. The most recent momentum reading is +6.7%, with net assets of CN¥2.46 Billion CNY as of December 2024. See 300357 net assets for net asset value and shareholders' equity analysis.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Net Asset Momentum by Year (2009–2024)
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd net asset momentum by year from 2009 to 2024. The table below shows the complete annual net asset history for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024, covering 16 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see Zhejiang Wolwo Bio-Pharmaceutical Co Ltd market cap and net worth.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | CN¥2.46 Billion | CN¥2.71 Billion | CN¥250.30 Million | ▲ +6.7% |
| 2023 | CN¥2.30 Billion | CN¥2.56 Billion | CN¥258.46 Million | ▲ +13.6% |
| 2022 | CN¥2.03 Billion | CN¥2.20 Billion | CN¥170.76 Million | ▲ +12.8% |
| 2021 | CN¥1.80 Billion | CN¥1.93 Billion | CN¥135.36 Million | ▲ +17.6% |
| 2020 | CN¥1.53 Billion | CN¥1.60 Billion | CN¥76.61 Million | ▲ +13.0% |
| 2019 | CN¥1.35 Billion | CN¥1.43 Billion | CN¥76.25 Million | ▲ +35.8% |
| 2018 | CN¥995.42 Million | CN¥1.06 Billion | CN¥62.47 Million | ▲ +24.2% |
| 2017 | CN¥801.26 Million | CN¥848.31 Million | CN¥47.05 Million | ▲ +22.2% |
| 2016 | CN¥655.58 Million | CN¥696.89 Million | CN¥41.32 Million | ▲ +12.5% |
| 2015 | CN¥582.91 Million | CN¥611.49 Million | CN¥28.57 Million | ▲ +13.5% |
| 2014 | CN¥513.55 Million | CN¥531.31 Million | CN¥17.75 Million | ▲ +103.9% |
| 2013 | CN¥251.92 Million | CN¥263.95 Million | CN¥12.04 Million | ▲ +38.9% |
| 2012 | CN¥181.38 Million | CN¥191.11 Million | CN¥9.73 Million | ▲ +42.1% |
| 2011 | CN¥127.61 Million | CN¥147.19 Million | CN¥19.58 Million | ▲ +41.1% |
| 2010 | CN¥90.44 Million | CN¥110.52 Million | CN¥20.08 Million | ▼ -19.2% |
| 2009 | CN¥111.89 Million | CN¥121.38 Million | CN¥9.49 Million | — |